TP53 and colorectal cancer: Another is a phase II trial investigating the effect of atorvastatin for treating patients with ulcerative colitis who have a dominant-negative missense TP53 mutation and are at risk of developing large intestinal cancer (ClinicalTrials.gov Identifier: NCT04767984).